These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 808641)

  • 21. Suppression of BCG cell wall-induced delayed-type hypersensitivity by pretreatment with killed BCG: induction of nonspecific suppressor T cells by the adjuvant portion (MDP) and of specific suppressor T cells by the antigen portion (TAP).
    Kato K; Yamamoto K; Kimura T; Azuma I; Askenase PW
    J Immunol; 1984 Jun; 132(6):2790-5. PubMed ID: 6202761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infection with Bacillus Calmette-Guérin activates murine thymus-independent (B) lymphocytes.
    Sultzer BM
    J Immunol; 1978 Jan; 120(1):254-61. PubMed ID: 342604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppressor cells in the spleen of tumor-allosensitized mice.
    Argyris BF
    Cancer Res; 1977 Sep; 37(9):3390-9. PubMed ID: 141979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunogenetic analysis of delayed hypersensitivity to tuberculin in mice by the method of local adoptive transfer].
    Mezhlumova MB
    Probl Tuberk; 1990; (4):55-8. PubMed ID: 2395849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin.
    Orme IM; Collins FM
    Cell Immunol; 1984 Mar; 84(1):113-20. PubMed ID: 6421492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice.
    Kawamura I; Tsukada H; Yoshikawa H; Fujita M; Nomoto K; Mitsuyama M
    J Immunol; 1992 May; 148(9):2887-93. PubMed ID: 1374103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opposite effects of cyclophosphamide pretreatment on tuberculin hypersensitivity during the course of sensitization of mice with Mycobacterium bovis BCG.
    Turcotte R
    Int J Immunopharmacol; 1985; 7(5):687-95. PubMed ID: 4044094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro cytotoxicity expressed by cells active against established tumors in vivo.
    Tuttle RL; Knick VC; Stopford CR; Weck CJ; Wolberg G
    Cancer Res; 1981 Jul; 41(7):2633-9. PubMed ID: 6788359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor.
    Hawrylko E; Mele CA; Stutman O
    Cell Immunol; 1982 Jan; 66(1):139-51. PubMed ID: 6805960
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants.
    Hernández A; Yager JA; Wilkie BN; Leslie KE; Mallard BA
    Vet Immunol Immunopathol; 2005 Mar; 104(1-2):45-58. PubMed ID: 15661330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor bearer T cells suppress BCG-potentiated antitumor responses. I. Requirements for their effect.
    Hawrylko E
    Cell Immunol; 1982 Jan; 66(1):121-38. PubMed ID: 6211241
    [No Abstract]   [Full Text] [Related]  

  • 32. Selective localization of tumor-immune spleen cells at the tumor challenge site after adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs.
    de Jong WH; van de Plas MM; Steerenberg PA; Kruizinga W; Ruitenberg EJ
    J Immunol; 1985 Mar; 134(3):2032-40. PubMed ID: 2578526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration of the immune response to Mycobacterium bovis BCG in mice exposed chronically to low doses of UV radiation.
    Jeevan A; Kripke ML
    Cell Immunol; 1990 Oct; 130(1):32-41. PubMed ID: 2204482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo antitumor activity of various forms of delayed-type hypersensitivity in mice.
    Lagrange PH; Thickstun PM
    J Natl Cancer Inst; 1979 Feb; 62(2):429-36. PubMed ID: 283275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A possible relationship between delayed hypersensitivity and cell-mediated immunity.
    Salvin SB; Neta R
    Am Rev Respir Dis; 1975 Apr; 111(4):373-7. PubMed ID: 47728
    [No Abstract]   [Full Text] [Related]  

  • 36. Cutaneous unresponsiveness to Mycobacterium bovis BCG in intravenously infected mice.
    Turcotte R; Forget A
    Infect Immun; 1983 Aug; 41(2):453-61. PubMed ID: 6347889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The lymphocyte mediators of delayed hypersensitivity: the early phase cells.
    Lefford MJ; McGregor DD
    Immunology; 1978 Apr; 34(4):581-90. PubMed ID: 721132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed type hypersensitivity and antituberculous immunity.
    Averbakh MM; Gergert VY; Kluyev VA; Kolodiazhnaya NS; Litvinsov VI; Moroz AM
    Z Immunitatsforsch Exp Klin Immunol; 1974 Aug; 147(3):204-16. PubMed ID: 4283014
    [No Abstract]   [Full Text] [Related]  

  • 39. Mode of immunopotentiating action of BCG: persistence and spread of BCG infection.
    Ishibashi T; Harada Y; Harada S; Yamada H; Takamoto M; Sugiyama K
    Jpn J Exp Med; 1978 Jun; 48(3):227-32. PubMed ID: 362025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of delayed-type hypersensitivity to Trypanosoma cruzi in mice treated with Mycobacterium bovis BCG and cyclophosphamide.
    Abrahamsohn IA; Blotta MH; Curotto MA
    Infect Immun; 1981 Mar; 31(3):1145-51. PubMed ID: 6785239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.